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Abstract
Background
There is a lack of evidence on the effectiveness or cost-effectiveness of alternative brands
of prosthesis for total knee replacement (TKR). We compared patient-reported outcomes,
revision rates, and costs, and estimated the relative cost-effectiveness of five frequently
used cemented brands of unconstrained prostheses with fixed bearings (PFC Sigma, AGC
Biomet, Nexgen, Genesis 2, and Triathlon).
Methods
We used data from three national databases for patients who had a TKR between 2003 and
2012, to estimate the effect of prosthesis brand on post-operative quality of life (QOL) (EQ-
5D-3L) in 53 126 patients at six months. We compared TKR revision rates by brand over 10
years for 239 945 patients. We used a fully probabilistic Markov model to estimate lifetime
costs and quality-adjusted life years (QALYs), incremental cost effectiveness ratios
(ICERs), and the probability that each prosthesis brand is the most cost effective at alterna-
tive thresholds of willingness-to-pay for a QALY gain.
Findings
Revision rates were lowest with the Nexgen and PFC Sigma (2.5% after 10 years in 70-
year-old women). Average lifetime costs were lowest with the AGC Biomet (£9 538); mean
post-operative QOL was highest with the Nexgen, which was the most cost-effective brand
across all patient subgroups. For example, for 70-year-old men and women, the ICERs for
the Nexgen compared to the AGC Biomet were £2 300 per QALY. At realistic cost per
QALY thresholds (£10 000 to £30 000), the probabilities that the Nexgen is the most cost-
effective brand are about 98%. These results were robust to alternative modelling
assumptions.
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Conclusions
AGC Biomet prostheses are the least costly cemented unconstrained fixed brand for TKR
but Nexgen prostheses lead to improved patient outcomes, at low additional cost. These
results suggest that Nexgen should be considered as a first choice prosthesis for patients
with osteoarthritis who require a TKR.
Introduction
Over a million total knee replacements (TKR) are performed worldwide each year [1]. In 2011,
the global market for knee prostheses was estimated to be $7 billion and it is projected to reach
$11 billion by 2017 [2]. Most knee replacements use cement to fix the components of the pros-
thesis to the bone, preserve supporting ligaments (unconstrained prostheses), and have fixed
tibial bearings [3].
A large number of knee prostheses have been introduced on the market and more than sixty
different prosthesis brands were implanted in England andWales in 2012 [4]. Randomised
controlled trials (RCTs) have compared different types of TKR [5,6], but there are no RCTs
comparing brands, and observational studies are inconclusive [7,8]. Evidence on the revision
rates of the prosthesis and patients’ quality of life (QOL) according to brand is available from
national joint registers [9–11]. In 2013, the National Joint Registry for England, Wales and
Northern Ireland (NJR), the world’s largest database of patients who had a knee replacement,
reported eight-year revision rates for the five most commonly used cemented, unconstrained
brands with fixed bearings of 2.1% for PFC Sigma, 2.3% for Genesis 2, 2.4% for Nexgen, 2.8%
for AGC Biomet, and 2.9% for Triathlon without case-mix adjustment [11]. A study using a
sample of patients included in the NJR found that those who had received a Nexgen prosthesis
had the least severe symptoms and best quality of life six months after the replacement proce-
dure [12].
In this paper, we evaluate the relative cost-effectiveness of these five brands which together
cover about 60% of the market in the UK and are among the most commonly used brands in
many other countries. The study estimated lifetime cost-effectiveness for patients with osteoar-
thritis, separately for men and women undergoing surgery at three different age (60, 70, and 80
years). We estimated the effect of prosthesis brand on QOL using data from a national pro-
gramme that collects patient-reported outcome measures (PROMs) immediately before and
six months after an elective TKR in the English National Health Service (NHS), the world’s
largest database of QOL outcomes following joint replacements [13].
Methods
Model overview
AMarkov model with a cycle length of one year was used to simulate the longevity of the knee
prosthesis brands over the patients’ lifetime [14]. This model is adapted from a published eval-
uation of alternative types of total hip replacement, as failure of the prosthesis is the primary
concern for both hip and knee replacement [15]. For each brand, costs and outcomes were esti-
mated for a hypothetical cohort of patients who enter the model at the time of the primary
TKR (Fig 1). After the primary replacement, patients face a possibility of immediate post-oper-
ative mortality, and then annual probabilities of revision of the TKR and mortality. Patients
requiring revision move to the ‘Revision’ state. After successful recuperation patients then tran-
sit to the ‘Revised TKR’ state.
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Time spent in health states after primary and revision TKR was weighted for QOL and
summed over 45 cycles to estimate life expectancy in terms of quality-adjusted life years
(QALYs). Lifetime costs from a health care perspective were calculated by summing the cost of
the primary TKR and any subsequent revision procedure. We tested whether the model’s main
assumptions (see Box 1) were robust to alternative assumptions in sensitivity analyses.
Data sources
Overview. We used individual patient data from the English National PROMs Programme
[13], linked to records from the NJR [11] and the English Hospital Episode Statistics (HES)
database [16] to estimate the effect of TKR brand on post-operative QOL and length of stay
(LOS). QOL in the primary TKR state was parameterised using post-operative data after pri-
mary TKR. QOL in the revision state was parameterised using pre-operative data after revision
TKR. QOL in the revised TKR state was parameterised using post-operative data after revision
TKR. We estimated revision rates by prosthesis brand using NJR data. Re-revision rates and
mortality were estimated from HES data.
QOL, pre-operative characteristics and prosthesis type
Data from the National PROMs Programme included patients who had an elective TKR
between August 2008 and July 2012 [13]. This programme collects patient-reported comorbid-
ities and QOL immediately before the TKR and QOL six month thereafter. The Oxford Knee
Score (OKS) is a 12-item disease-specific instrument which generates scores ranging from 0
(worst health status) to 48 (best health status) [17]. The EQ-5D-3L is a generic instrument
which generates health profiles using five dimensions (mobility, self-care, usual activities, pain
and discomfort, anxiety and depression) and three levels (no problems, some problems, severe
problems) [18]. These profiles were combined with health state preference values from the UK
general population, to give EQ-5D-3L utility index scores on a scale anchored at 0 (death), and
1 (perfect health) [19].
Fig 1. Markovmodel of TKR
doi:10.1371/journal.pone.0150074.g001
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We accessed pre-operative PROMs records for 158 799 patients aged 55 to 84 years, and
subsequently included 105 637 patients whose record could be linked to NJR and HES records.
The NJR provided data on prosthesis type, diagnosis (osteoarthritis or other), body mass index
(BMI), and American Society of Anesthesiologists (ASA) grade [20]. HES provided data on
socioeconomic deprivation derived from the patient’s postcode as the Index of Multiple Depri-
vation (IMD) [21].
We excluded patients who had missing data on prosthesis brand, those who had any diag-
nosis other than osteoarthritis or an ASA grade worse than 3; and those who received a
cementless prosthesis component or a non-standard surgical procedure such as a bone-graft.
The resulting sample of 53 126 patients was used to estimate LOS and QOL six months after
TKR. These QOL estimates were applied to patients in the primary TKR health state in the ini-
tial cycle and each subsequent cycle. After each cycle of the Markov model we reduced QOL in
each health state to reflect the effect of aging. The magnitude of the reduction increased with
age (for example the reduction was 0.004 in QOL tariff at age 70) reflecting the curvilinear rela-
tionship observed in a large UK observational study [22].
For the health state representing the year in which patients had a TKR revised, QOL and
LOS was taken from pre-operative data for 6 128 patients whose TKR was a revision. For subse-
quent years, QOL was taken from the 3 912 patients who had responded to outcome question-
naires six months after the revision surgery.
Box 1. Main assumptions underlying the Markov model of the cost
effectiveness analysis.
• Patients enter the model at the time they have the TKR. The model assumes that the
post-operative QOL observed at six months, applies from when the patients enter the
model, and to subsequent model cycles in the TKR health state.
• The differences observed in QOL across prosthesis types six months after TKR is main-
tained for the lifetime, subject to the decline in QOL with increasing age, and the possi-
bility that the TKR fails.
• The approach to estimate the effect of prosthesis type on QOL has fully addressed
confounding.
• Deterioration of the prosthesis does not affect QOL adversely unless the prosthesis is
revised.
• All failed prostheses are revised.
• The effect of prosthesis failure on QOL is estimated from the QOL observed before sur-
gery in those who had a revision, and is applied for one year post revision.
• The approach to extrapolate prosthesis survival beyond the observed data accurately
predicts the long term probability of prosthesis survival.
• The costs of revising the TKR are same for each prosthesis brand.
• QOL during and after revision is the same whether or not the revision was undertaken
due to sepsis.
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Rates of revision and re-revision. The annual revision rates after a primary TKR accord-
ing to prosthesis brand were estimated from NJR data. We accessed 265 910 records of patients
who had a primary, unilateral TKR between 1 April 2003 and 1 March 2012, who were aged
between 55 and 84, who had a primary diagnosis of osteoarthritis, and who received treatment
in an NHS hospital or treatment centre. Records for 239 945 patients were available for analysis
after applying the same exclusion criteria we applied to the PROMs data. The data contained 3
148 linked revisions recorded in the NJR (593 PFC Sigma, 392 AGC Biomet,129 Nexgen, 112
Genesis 2, 74 Triathlon, and 1 848 other brands). Maximum observation periods varied by
brand from 11.1 years for the PFC Sigma to 6.7 years for the Triathlon.
Re-revision rates were estimated from the records of 54 134 patients with a revision
recorded in HES between April 1997 and March 2012, after linking initial and subsequent revi-
sions on the same knee.
Mortality. Operative mortality after TKR was estimated from HES data. We did not find
any difference in operative mortality across prostheses brands (p>0.4) after adjusting for
potential confounders (age, sex, ASA grade, BMI, funding source and date of surgery), and
therefore we applied the same probabilities of death across all prosthesis brands. Annual mor-
tality according to age and sex was taken from general population data, after using HES data to
adjust for the “healthy patient” effect, to recognise that patients who have undergone joint
replacement for osteoarthritis have a lower mortality than observed in the general population
[23]. The healthy patient effect was largest for older patients (relative risk of dying was 0.3 for
males aged 80 in the year after surgery) and decayed exponentially to a relative risk of 1.0 over
the decade following surgery.
Costs. All costs are reported in British pounds (1 British pound 1.60 US dollars 1.20
euros) according to 2011–12 prices. The unit cost of each prosthesis brand was taken from the
average prices paid by a mid-size NHS provider (including all components and instrumenta-
tion) to reflect discounts negotiated on list prices: £1 835 for PFC Sigma, £1 150 for AGC Bio-
met, £1 676 for Nexgen, £1 294 for Genesis 2, and £1 325 for Triathlon (Lewis P. NHS
SupplyChain. Personal Communication).
Unit costs of the operating theatre for a primary TKR (£2 022) and a hospital bed day
(£332) were based on data from a recent RCT carried out in the UK [24]. The unit costs of revi-
sions (£8 429) recognised that more resources are used than for primary surgery [24].
Statistical analysis to provide input parameters for the cost-effectiveness
model
QOL after primary TKR and revision. We estimated QOL following primary TKR
according to prosthesis brand using linear regression to adjust for observed differences in pre-
operative patient and provider characteristics between the comparison groups. We adjusted for
the following differences in case mix: age, sex, comorbidities, BMI, disability, ASA grade, IMD,
patella replacement, surgical position, pre-operative EQ-5D-3L and OKS scores. To avoid
attributing differences arising from surgeon or hospital factors to prosthesis brand, we also
adjusted for provider characteristics (surgeon experience [senior surgeon or not], and hospital
type [specialist treatment centre or general hospital]).
We applied fractional polynomials to continuous variables where they provided an
improvement in model fit over linear or quadratic functions [25]. We then predicted post-
operative QOL by prosthesis brand separately for men and women in three different age
groups (60, 70 and 80 years). QOL in the year during which revision TKR took place, and
in subsequent years after revision was predicted according to age and sex using linear
regression.
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Of the 53 126 patients included in the QOL analysis 17% were missing post-operative
PROMs. Most other data items were missing for less than 10% of the sample. Multiple imputa-
tion using chained equations was applied to pre- and post-operative data to impute missing
responses [26]. Twenty imputations were undertaken and results across these imputations
were combined by Rubin’s rules [27].
Rate of revision and re-revision. Annual revision rates were predicted from NJR data for
each prosthesis brand after adjusting for differences between the comparison groups. We
adjusted for differences in case mix (age, sex, ASA grade, BMI, patella replacement, antibiotic
cement) and provider characteristics (surgeon experience, and hospital type). We used a
restricted cubic spline regression model to capture the underlying variation in revision rates over
time, without imposing a pre-specified relationship, and to allow extrapolation of revision rates
beyond the observation period [28]. To meet the requirements of the Markov model, re-revision
rates were estimated from HES data with a piece-wise constant survival regression model which
differentiated revision rates at only one time point: the first year versus all subsequent years.
Cost-effectiveness analysis
For men and women aged 60, 70 and 80, the cost-effectiveness model reported revision rates,
costs related to TKR, and QALYs for patients with the average pre-operative characteristics for
each subgroup. A recommended annual discount rate of 3.5% was applied to both costs and
outcomes to reflect societal time preferences [29].
We report the incremental costs per QALY, and the probability that each prosthesis brand
is the most cost-effective. We recognised sampling uncertainty in the estimation of the model
parameters by undertaking a probabilistic analysis. Model results are reported after averaging
across 1 000 simulations in which each model parameter was sampled from the appropriate
probability distribution.
For each brand of TKR, we calculated the net monetary benefit by multiplying total lifetime
QALYs by society’s willingness-to-pay for a QALY gain and subtracting from this the total life-
time cost. The calculation was repeated with alternative levels of willingness-to-pay for a
QALY gain (from £0 to £50 000). We calculated cost-effectiveness acceptability frontiers to
report the brand with the highestmean net monetary benefit (most cost-effective on average)
and the proportion of simulations for which this brand had the highest net monetary benefit
(recognising sampling variation), at different levels of willingness-to-pay for a QALY gain [30].
Sensitivity analyses. We tested whether the results were robust to alternative assumptions
about post-operative QOL, revision rates and costs across brands. First, we assumed that differ-
ences in post-operative QOL between prosthesis brands were only maintained for one year
after TKR, rather than until a revision or death. Second, we considered an alternative form of
linear regression model to estimate post-operative QOL across TKR brands by including inter-
action terms between prosthesis brand and both age and sex. Third, in the linear regression
model that estimated the effect of brand on post-operative QOL, rather than including a single
continuous variable for the baseline EQ-5D-3L, we specified categorical variables for each
health state dimension. Fourth, we considered an alternative form of the regression model used
for the prediction of revision rates by using a piece-wise constant rather than a restricted cubic
spline hazard function. Fifth, we applied the same prosthesis cost to each brand.
The Markov model was built in Excel; statistical analysis to parameterize the model was
undertaken in STATA version 11.
The study is exempt UK NREC approval as it involved analysis of existing datasets of anon-
ymised data for service evaluation. Approvals for the use of HES data were obtained as part of
the standard Hospital Episode Statistics approval process.
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Results
Patient characteristics before the total knee replacement
The pre-operative characteristics of the sample of 53 126 patients who were used for estimating
the effect of prosthesis brand on post-operative QOL were very similar across brands (Table 1).
However, patients receiving the PFC Sigma and the Triathlon were more likely to have had the
TKR at an independent sector treatment centre and by a consultant, than those receiving the
other three brands.
Initial outcomes and costs after primary TKR
After adjustment for pre-operative characteristics, the mean OKS, and EQ-5D-3L score six
months after the primary TKR was highest in those receiving a Nexgen and lowest in those
receiving a Genesis 2 (Table 2). Revision rates at 5 and 10 years were lowest with the Nexgen
and PFC Sigma brands and highest with the AGC Biomet (Table 2). Initial costs were lowest
with the AGC Biomet and highest with the PFC Sigma.
Table 1. Characteristics of 53 126 patients according to knee prosthesis brands with multiple imputation of missing data.
Prosthesis Brand
PFC Sigma AGC Biomet Nexgen Genesis 2 Triathlon
No. of patients 13 635 5 005 3 364 4 187 3 585
Mean (SD) age (years) 69.9 (7.3) 70.5 (7.3) 69.8 (7.3) 70.1 (7.3) 69.9 (7.3)
Proportion Male (%) 45 44 45 44 43
Most deprived ﬁfth (%) 20 16 21 22 23
Two or more comorbidities (%) 30 29 30 29 28
ASA grade 3 or higher (%) 16 17 18 16 18
Mean (SD) BMI (kg/m2) 31.3 (5.5) 31.4 (5.7) 31.4 (5.6) 31.3 (5.5) 31.0 (5.6)
Operation at Independent sector treatment centre (%) 10 2 0 1 14
Operation by consultant (%) 84 79 76 77 82
Pre-operative mean (SD) OKS 18.5 (7.6) 19.0 (7.7) 18.6 (7.4) 19.0 (7.6) 18.8 (7.7)
Pre-operative mean (SD) EQ-5D-3L index 0.38 (0.31) 0.41 (0.31) 0.39 (0.31) 0.41 (0.31) 0.40 (0.31)
doi:10.1371/journal.pone.0150074.t001
Table 2. Initial QOL, OKS, initial cost and revision rates after primary TKR, according to brand with adjustment for pre-operative differences in
case mix, for men and women aged 70.
Prosthesis Brand
PFC Sigma AGC Biomet Nexgen Genesis 2 Triathlon
Men aged 70
Post-operative mean EQ-5D-3L index 0.73 0.72 0.74 0.71 0.72
Post-operative mean OKS score 35.4 35.4 36.0 34.2 35.3
Mean cost of primary replacement (£) 5 414 4 574 5 233 5 229 5 006
5-year revision rate 2.1% 2.8% 2.1% 2.4% 2.5%
10-year revision rate 3.1% 4.2% 3.1% 3.7% 3.8%
Women aged 70
Post-operative mean EQ-5D-3L index 0.72 0.71 0.73 0.70 0.71
Post-operative mean OKS score 33.9 33.8 34.4 32.6 33.7
Mean cost of primary replacement (£) 5 491 4 651 5 311 5 306 5 084
5-year revision rate 1.6% 2.2% 1.6% 1.9% 2.0%
10-year revision rate 2.5% 3.3% 2.5% 2.9% 3.0%
doi:10.1371/journal.pone.0150074.t002
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Cost-effectiveness analysis
For both men and in women, the average lifetime costs were lowest in those who received an
AGC Biomet and highest in those who received a PFC Sigma (Table 3). Patients who had a
Nexgen prosthesis had the highest expected quality-adjusted life expectancy (QALYs). The
Genesis 2 and Triathlon brands were “dominated” by the AGC Biomet as they had lower aver-
age lifetime QALYs and higher mean costs (Fig 2). The PFC Sigma was dominated by the Nex-
gen. For 70-year old men and women the incremental cost-effectiveness ratio for receiving a
Nexgen compared to an AGC Biomet prosthesis was approximately £2 300 per QALY.
Similarly, the cost-effectiveness results in Table 3 and the acceptability frontiers in Fig 3
demonstrate that for patients aged 70, the Nexgen is highly likely to be the most cost-effective
brand, or in other words, had the highest net monetary benefit from the vast majority of the 1
000 model simulations. If the societal willingness-to-pay per QALY exceeds £10 000, the proba-
bility that the Nexgen is the most cost-effective prosthesis brand exceeds 98% for men and
women aged 70. A similar pattern of results was observed for men and women age 60 and 80
and the Nexgen is therefore also highly likely to be the most cost-effective brand for these age
groups.
Sensitivity analyses
The finding that the Nexgen was the most cost-effective brand was robust to alternative
assumptions (Table 4). When differences in post-operative QOL between brands were assumed
to be maintained for only one year, and when the linear regression analysis estimating the effect
of brand on post-operative QOL included interactions between brand, age and sex, the results
were somewhat more uncertain. However, the probability that the Nexgen is the most cost-
effective prosthesis is always 75% or above for each subgroup at a willingness-to-pay threshold
of £20 000 per QALY.
Discussion
Our cost-effectiveness analysis found that the Nexgen was the most cost-effective cemented,
unconstrained, fixed prosthesis brand for patients with osteoarthritis who have a primary
TKR. Selection of the Nexgen over the other four most commonly used brands would generate
Table 3. Mean lifetime costs, lifetime QALYs, and proportion of patients undergoing revision and net monetary benefit for men and women aged
70.
Prosthesis Brand
PFC Sigma AGC Biomet Nexgen Genesis 2 Triathlon
Men aged 70
Lifetime proportion revised 3.9% 5.1% 3.8% 4.5% 4.6%
Mean lifetime cost (£) 5 900 5 226 5 721 5 799 5 600
Mean lifetime QALYs 7.57 7.50 7.72 7.38 7.50
Net monetary beneﬁt at £20,000 per QALY (£) 145 553 144 818 148 658 141 867 144 343
Incremental Cost-effectiveness ratio (ICER) dominated base 2 284 dominated dominated
Women aged 70
Lifetime proportion revised 3.3% 4.5% 3.3% 3.9% 4.0%
Mean lifetime cost (£) 5 876 5 166 5 696 5 756 5 553
Mean lifetime QALYs 8.27 8.20 8.44 8.06 8.19
Net monetary beneﬁt at £20,000 per QALY (£) 159 556 158 819 163 012 155 498 158 289
Incremental Cost-effectiveness ratio (ICER) dominated base 2 244 dominated dominated
doi:10.1371/journal.pone.0150074.t003
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Fig 2. Cost-effectiveness planes for men and women aged 70. The axis represents differences in lifetime QALYs and cost compared to those of AGC, the
prosthesis brand with the lowest lifetime cost.
doi:10.1371/journal.pone.0150074.g002
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better outcomes for patients at low additional costs. These results have implications for many
countries as the five included prosthesis brands represent the majority of prostheses implanted
for example in Sweden, Finland, Denmark, Australia, New Zealand and the US [9,31–35].
This is the first study to compare the cost-effectiveness of commonly used brands of knee
prosthesis. Previous comparisons across brands only reported revision rates or symptom sever-
ity and post-operative QOL [9,10,12,36]. We synthesised evidence on revision rates, post-oper-
ative QOL and costs and found that relatively small differences in post-operative QOL are the
key determinants of relative cost-effectiveness. For example, patients who received the Nexgen
had the highest post-operative QOL but similar 5-year and 10-year revision rates compared to
the PFC Sigma, the market leader in the UK. In our previous cost-effectiveness analysis of alter-
native types of total hip replacement we also found that the relative effect on post-operative
QOL was the key driver of cost-effectiveness [15]. This highlights the importance of having
data from a large national PROMs programme linked to the NJR.
Whilst other joint registries have a longer follow-up than the NJR, the value of older data is
limited given the recognised gradual improvement of joint replacement outcome in the last
decade [37] and the ongoing introduction of new knee prostheses. Moreover, we were able to
exploit the linkage of PROMs data to both HES and the NJR which allowed us to quantify
small but potentially important differences in post-operative QOL between brands while care-
fully adjusting for differences in patient and provider characteristics across brands.
It should be acknowledged that residual confounding is a potential explanation of small
differences between treatment groups in observational studies irrespective of their size.
Fig 3. Cost-effectiveness acceptability frontiers, 70 year olds, base case.Only the result of the prosthesis brand with the highest average net monetary
benefit for a given willingness-to-pay threshold is presented in the figure.
doi:10.1371/journal.pone.0150074.g003
Table 4. Proportion of 1 000 simulations that a knee prosthesis brand gave the highest net monetary benefit at £20 000 per QALY for men and for
women aged 70 in the base case and sensitivity analyses.
Proportion of 1 000 simulations in which the prosthesis
was the most cost-effective (achieved the highest net
monetary beneﬁt) by brand
PFC
Sigma
AGC
Biomet
Nexgen Genesis
2
Triathlon
Scenario Men aged 70
Base case 0006 0 0994 0 0
Differences in QOL between brands only maintained in ﬁrst year after TKR 0003 0131 0843 0 0023
Interaction between brand, age and sex included in regression model for prediction of
post-operative QOL
0013 0099 0825 0 0063
Pre-operative QOL speciﬁed using dummies for EQ-5D responses 0003 0 0997 0 0
Piece-wise constant hazard function for prediction of revision rate 0018 0011 0965 0 0006
Same prosthesis cost for all brands 0002 0 0998 0 0
Women aged 70
Base case 0003 0 0996 0 0001
Differences in QOL between brands only maintained in ﬁrst year after TKR 0 0226 0750 0 0024
Interaction between brand, age and sex included in regression model for prediction of
post-operative QOL
0003 0003 0994 0 0
Pre-operative QOL speciﬁed using dummies for EQ-5D responses 0003 0 0996 0 0001
Piece-wise constant hazard function for prediction of revision rate 0022 0007 0967 0 0004
Same prosthesis cost for all brands 0006 0 0994 0 0
doi:10.1371/journal.pone.0150074.t004
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However, in estimating the effects of prosthesis brand on QOL and revision rates, we
adjusted for a wide range of case mix variables including pre-operative symptom severity,
comorbidity and BMI. Also, our sensitivity analysis demonstrated that even with alternative
specifications of the linear regression model used to adjust for pre-operative case mix differ-
ences, the Nexgen remained the most cost-effective prosthesis. Lastly, the choice of prosthesis
brand depends on the hospital and the surgeons providing the treatment rather than on the
pre-operative characteristics of the patient, which reduces the risk of residual confounding
even further. Two thirds of hospitals in England use a single brand for the majority of
patients because it is advantageous for hospitals to use one brand from a single supplier for
most patients as that would allow them to negotiate a discounted price. We did not undertake
hierarchical modelling to estimate post-operative QOL and consequently there is a possibility
that we under-estimated uncertainty around differences in post-operative QOL and in the
resultant estimates of cost-effectiveness.
Post-operative QOL was based on data collected 6 months after TKR. There is some evi-
dence of relatively small further gains in QOL beyond 6 months [38]. However, this increase is
small and unlikely to influence the relative differences between the brands. In addition, our
sensitivity analysis demonstrated that the cost-effectiveness results are robust to variations in
the duration that the differences in post-operative QOL between prosthesis brands are
maintained.
Our analysis did not explore the reasons for differences in QOL outcomes or revision rates
between brands. The prosthesis design factors influencing revision rates and QOL are complex
and multifactorial. Nevertheless, Joint registries show improvement in design over time. Our
findings are consistent with a previous report of the superiority of QOL outcomes with the
Nexgen prosthesis [12].
We obtained information on the costs of the prosthesis brands from NHS SupplyChain, an
organisation that provides NHS hospitals with equipment and materials they need for patient
care. Using these national costs has the advantage they represent the actual costs paid in the
UK rather than a list price. We expect that in other countries, existing market mechanisms
would produce a similar price pattern across the brands. However sensitivity analysis in which
each prosthesis brand was assigned the same cost suggest the results are not sensitive to varia-
tion in prosthesis costs.
In conclusion, our study found that the initial and lifetime costs of the Nexgen prosthesis
are lower than the PFC Sigma, the market leading brand, and that patients who received the
Nexgen knee prosthesis have higher lifetime QALYs compared to four commonly used alterna-
tive brands of unconstrained, fixed prosthesis. The Nexgen prosthesis is therefore the most
cost-effective brand, across all patient subgroups. These results suggest that the Nexgen should
be considered as a first choice prosthesis for patients with osteoarthritis who require a TKR.
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